An update on immunotherapy with PD-1 and PD-L1 blockade

Area of Science:

• Oncology
• Immunology

Background:

• Cancer remains a leading global cause of death, with treatment historically focusing on growth mechanisms.
• Immune checkpoint inhibitors targeting tumor immunity have emerged as a significant advancement since 2010.
• Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors have gained FDA approval for various cancers.

Purpose of the Study:

• To address the limitations of single-agent immunotherapy.
• To explore combination strategies to enhance cancer treatment efficacy.

Main Methods:

• Review of studies on combination therapy in oncology.
• Analysis of immunotherapy combined with conventional treatments like chemotherapy and targeted agents.

Main Results:

• Immune checkpoint inhibitors demonstrate durable responses but have limited response rates (15-20%).
• Combination therapies have shown improved response rates and efficacy in multiple cancer types.
• Specific examples include non-small cell lung cancer, small cell lung cancer, breast cancer, and urogenital cancers.

Conclusions:

• Combination strategies integrating immunotherapy with chemotherapy or targeted agents represent a key advancement in cancer treatment.
• These combined approaches are crucial for overcoming the low response rates associated with individual immunotherapies.
• Further research into combination therapies holds significant potential for improving patient outcomes in oncology.